Literature DB >> 16246930

VIP Inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes.

N Foster1, J Cheetham, J J Taylor, P M Preshaw.   

Abstract

Lipopolysaccharide (LPS) from the Gram-negative pathogen Porphyromonas gingivalis (Pg) stimulates cytokine secretion in immune cells, and thereby initiates the inflammation associated with periodontitis. Modulation of pro-inflammatory cytokine activity is a plausible therapeutic target in periodontal disease. Vasoactive intestinal peptide (VIP) has a role in immunoregulation, and has been identified as a molecule with therapeutically beneficial immunosuppressive effects in inflammatory and autoimmune conditions. We aimed to investigate the effect of VIP on immune responses induced by Pg LPS in vitro. VIP (10(-8) M) significantly (P < 0.05) inhibits TNF-alpha production by human monocytic THP1 cells stimulated with Pg LPS. In parallel, we showed that VIP inhibits nuclear translocation of NFkappaB and c-Jun in a time-dependent manner, but does not decrease the expression of CD14 receptors. This is the first report to show the potential of VIP as an immunomodulator of Pg-stimulated inflammatory pathways in human monocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246930     DOI: 10.1177/154405910508401106

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  10 in total

1.  Osteomyelitis of the ulna caused by Porphyromonas gingivalis.

Authors:  Heike Welkerling; Walter Geissdörfer; Thomas Aigner; Raimund Forst
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  Effect of culture conditions on the phenotype of THP-1 monocyte cell line.

Authors:  Paulomi B Aldo; Vinicius Craveiro; Seth Guller; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2013-04-29       Impact factor: 3.886

Review 3.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

4.  Expression and regulation of interleukin-33 in human monocytes.

Authors:  Christopher J Nile; Emma Barksby; Paiboon Jitprasertwong; Philip M Preshaw; John J Taylor
Journal:  Immunology       Date:  2010-01-11       Impact factor: 7.397

5.  Phospholipase C, p38/MAPK, and NF-kappaB-mediated induction of MIP-3alpha/CCL20 by Porphyromonas gingivalis.

Authors:  Henrik Dommisch; Whasun O Chung; Søren Jepsen; Beth M Hacker; Beverly A Dale
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

6.  Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide.

Authors:  H E Barksby; C J Nile; K M Jaedicke; J J Taylor; P M Preshaw
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

7.  Transcriptional modulation by VIP: a rational target against inflammatory disease.

Authors:  Hiba Ibrahim; Paul Barrow; Neil Foster
Journal:  Clin Epigenetics       Date:  2011-05-18       Impact factor: 6.551

Review 8.  Role of vasoactive intestinal peptide in osteoarthritis.

Authors:  Wei Jiang; Hua Wang; Yu-Sheng Li; Wei Luo
Journal:  J Biomed Sci       Date:  2016-08-23       Impact factor: 8.410

Review 9.  The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis.

Authors:  Raúl Villanueva-Romero; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Iria V Seoane; Carmen Martínez; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Immunol Res       Date:  2018-08-01       Impact factor: 4.818

Review 10.  Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential.

Authors:  Daria Augustyniak; Judyta Nowak; Fionnuala T Lundy
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.